NEWS HIGHLIGHTS
Published Studies Related to Buprenex (Buprenorphine)
Buprenorphine medication versus voucher contingencies in promoting abstinence from opioids and cocaine. [2009.08]
During a 12-week intervention, opioid dependent participants (N = 120) maintained on thrice-a-week (M, W, F) buprenorphine plus therapist and computer-based counseling were randomized to receive: (a) medication contingencies (MC = thrice weekly dosing schedule vs... Findings should be interpreted in light of the greater attrition associated with medication-based contingencies versus the greater monetary costs of voucher-based contingencies.
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. [2009.08]
INTRODUCTION: The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation... CONCLUSIONS: Gastrointestinal symptoms of cancer pain patients undergoing an opioid therapy are related to multifactorial causes. Transdermal opioids showed no benefit over oral controlled-release hydromorphone with regard to gastrointestinal symptoms. The conversion ratios for transdermal fentanyl, transdermal buprenorphine, and oral hydromorphone did not accord to the literature, because of differing occurrences of opioid tolerance after long-term therapy.
The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. [2009.07.14]
BACKGROUND: In the United Kingdom (UK), there is an extensive market for the class 'A' drug heroin and many heroin users spend time in prison. People addicted to heroin often require prescribed medication when attempting to cease their drug use... Secondary outcomes will be recorded during the detoxification and then at one, three and six months post-detoxification.
[Prospective study on anesthesia for lumbar spine surgery--the effectiveness of the perioperative epidural anesthesia with buprenorphine] [2009.06]
We prospectively evaluated the efficacy of perioperative epidural buprenorphine for lumbar spinal surgery under general anesthesia. Twenty-eight patients were allocated into two groups; in one group (buprenorphine group), patients underwent the surgery under general anesthesia with perioperative epidural buprenorphine 0.2 mg, in the other group (control group), patients underwent the surgery under general anesthesia only...
Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. [2009.06]
BACKGROUND: Buprenorphine (BUP) is under investigation as a medication therapy for opioid-dependent pregnant women. We investigated BUP and metabolite disposition in urine from women maintained on BUP during the second and third trimesters of pregnancy and postpartum... CONCLUSIONS: These data are the first to evaluate urinary disposition of BUP and metabolites in a cohort of pregnant women. Variable BUP excretion during pregnancy may indicate metabolic changes requiring dose adjustment during later stages of gestation.
Clinical Trials Related to Buprenex (Buprenorphine)
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphin/Naloxone) in Opioid Dependent Patients on Subutex (Study P05094)(COMPLETED) [Completed]
This study is designed to determine if opioid dependent subjects who are already receiving
Subutex prefer the Suboxone tablet over the Subutex tablet after switching from Subutex to
Suboxone. Subjects who are selected to participate in this study will continue their
prescribed dose of Subutex (buprenorphin 2 to 16 mg daily) for the first two days of the
study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone
(buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5).
The Day 5 Visit will be the subject's last study visit. Upon completing the study, subjects
will continue their pre-study prescribed dosage of Subutex.
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir [Completed]
The main purpose of this study is to examine the effect of tipranavir combined with
ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in
people who have been receiving the same dose of buprenorphine/naloxone for at least 3 weeks
before study entry.
Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
The aim of the study is to determine whether buprenorphine maintenance versus detoxification
using buprenorphine, in prescription opioid dependent patients receiving primary care
management and drug counseling in an office-based setting, leads to decreased illicit opioid
use.
Safety and Tolerability of Buprenorphine/Naloxone Film Strips [Active, not recruiting]
This study will evaluate the safety and tolerability on the oral mucosa of
buprenorphine/naloxone film strips administered either sublingually or buccally daily for 12
weeks in opioid dependent individuals who are already on a stable regimen of
buprenorphine/naloxone.
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1) [Recruiting]
The purpose of this study is to assess the risks of abuse, misuse and adverse events related
to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or
its Buprenorphine High Dose (BHD) generic (Arrow Laboratories) will participate in this
study. Data will be collected using physician questionnaires and self evaluation patient
questionnaires at the first visit and visits at 6 and 12 months.
|
